ClinicalTrials.gg
CompletedNCT07233473UTIUpdated Oct 2, 2026

Evaluation of the Effectiveness and Safety of a Vaginal Gel for Prevention of Recurrent Urinary Tract Infections

An interventional study of Multi-Gyn UT Protect gel in Urinary Tract Infections (UTIs), sponsored by Karo Pharma AB. Completed at 1 site in France. Open to female participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Karo Pharma AB · Not applicable, Interventional, and Prevention

How we know

Updated Oct 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 84 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 58 studies in Urinary Tract Infections with a site in France — 10 open to participants now, 11 under way, 1 of them phase 3. Urinary Tract Infections · France.

Enrollment
23rd of 34
50 · median 131
Started
2025
the only one that year
No phase
19 of 58
3 open now
Registered
54th of 58
by date

Among the 58 studies in Urinary Tract Infections with a site in France, this one is the 23rd largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2025, is one of 19 with no phase, and was the 54th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

10 of the 58 studies in Urinary Tract Infections with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 84 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Urinary Tract Infections with a site in France, or all of them as a file.
02

Study summary

Urinary Tract Infections (UTIs) are among the most common bacterial infections. Although they are typically treated effectively with antibiotics, recurrence is a frequent and troublesome issue.

This clinical trial aims to evaluate the safety and effectiveness of Multi-Gyn UT Protect gel in preventing the recurrence of UTIs. The trial will involve 50 adult female participants who have experienced a UTI in recent months but do not currently have an active infection.

Each participant will apply the gel twice a week for four months. They will be monitored throughout this period to assess whether participants develop the reappearance of UTI symptoms.

The primary objective is to determine how many participants do not experience a recurrence of UTI by the end of the four-month treatment period.

03

Conditions studied

  • Urinary Tract Infections (UTIs)
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 to 84 years old.
  2. Sex: Female.
  3. Subject suffering from uncomplicated recurrent urinary tract infections: ≥ 4. UTIs within 12 months or ≥ 2 within 6 months.
  4. Subject having given freely and expressly her .
  5. Subject using a regimen recognized as effective (pill, implant, Intra Uterine Device (IUD), condoms) since at least 12 weeks before inclusion visit and during the whole study. If subject use condoms as contraceptive regimen, a delay of 6 hours between application and sexual intercourse must be respected.
  6. Subject affiliated to a health social security system.
  7. Subject cooperative and aware of the device's modalities of use and the necessity and duration of the follow-up visits so that perfect adhesion to the protocol can be expected.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or nursing woman or planning a pregnancy during the study.
  2. Subject who gave birth in the 3 previous months.
  3. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
  4. Subject in a social or sanitary establishment.
  5. Subject suspected to be non-compliant according to the investigator's judgment.
  6. Subject having received 6000 euros indemnities for participation in clinical research in the 12 previous months, including participation in the present study.
  7. Subject enrolled in another clinical trial or which exclusion period is not over.
  8. Subject with history of complicated urinary tract infection.
  9. Subject with urinary tract infection at the time of inclusion.
  10. Subject with vaginal mycosis infection in the last 3 weeks.
  11. Subject with recurrent vaginal mycosis (more than 2 in the last 6 months).
  12. Subject having a known allergy or to one of the components of the device.
  13. Subject suffering from a sexually transmitted gynaecological infection or aerobic vaginitis (including gonorrhoea, chlamydia trachomatis or mycoplasma genitalium infection with cervicitis, urethritis, salpingitis).
  14. Subject with history of hormone-dependent cancer or bladder cancer.
  15. Subject with current genital .
  16. Subject who had a chemotherapy treatment for a cancer in the 12 months before inclusion.
  17. Subject who had a radiotherapy treatment in the genito-urinary area in the 12 months before inclusion.
  18. Subject using treatment for urinary tract infection, vaginal conditions, vaginal infections, or other intravaginal treatment at the time of inclusion.
  19. Subject using food supplements for prevention of urinary tract infection in the last 3 months.
  20. Subject using antibiotics, corticoids or antifungal treatment for any reason in the 3 weeks before inclusion.
  21. Subject using vaginal douches and who do not wish to refrain using them during the clinical investigation.
  22. Subject with a pessary.
  23. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Study product

    Multi-Gyn UT Protect gel

    Device: Multi-Gyn UT Protect gel

Interventions

  • DeviceMulti-Gyn UT Protect gel

    Vaginal gel

06

What researchers measure

Primary outcomes

  1. To evaluate the effectiveness of Multi-Gyn UT Protect gel for the prevention of Urinary Tract Infection (UTI) relapse within 4 months

    The number of patients without UTI relapse within 4 months will be summarized in frequency (N) and percentage (%), with a confidential interval CI 95%.

    Time frame: 4 months

Secondary outcomes

  1. To evaluate the effectiveness of Multi-Gyn UT Protect gel for the prevention of UTI relapse within 1, 2 and 3 months

    The number of patients without UTI relapse within 1, 2, 3 months will be summarized in frequency (N) and percentage (%), with a confidential interval CI 95% by time point.

    Time frame: 1, 2 and 3 months

07

Study locations

1 site
  • Eurofins Dermscan Pharmascan
    Villeurbanne, 69100, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Apr 2026, 5 months.

Of 154 interventional studies with no phase under Urinary Tract Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 37. This study's 5 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Dec 2026 → Apr 2026 and completion Mar 2027 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Oct 20, 2025
Primary completionActual
Apr 3, 2026was Dec 2026
CompletionActual
Apr 3, 2026was Mar 2027
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 2, 2026
Primary completion
Dec 31, 2026→Apr 3, 2026 (actual)
Oct 2, 2026
Study completion
Mar 31, 2027→Apr 3, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2026→Apr 3, 2026 (now actual)
    Study completion Mar 31, 2027→Apr 3, 2026 (now actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07233473
Lead sponsor
Karo Pharma AB
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Oct 20, 2025
Primary completion
Apr 3, 2026
Completion
Apr 3, 2026
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion